NZ568367A - Treatment of malignant neoplasias using non-radioactive 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine - Google Patents

Treatment of malignant neoplasias using non-radioactive 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine

Info

Publication number
NZ568367A
NZ568367A NZ568367A NZ56836706A NZ568367A NZ 568367 A NZ568367 A NZ 568367A NZ 568367 A NZ568367 A NZ 568367A NZ 56836706 A NZ56836706 A NZ 56836706A NZ 568367 A NZ568367 A NZ 568367A
Authority
NZ
New Zealand
Prior art keywords
phenylalanine
iodo
use according
therapy
therapeutic
Prior art date
Application number
NZ568367A
Other languages
English (en)
Inventor
Samuel Samnick
Original Assignee
Samuel Samnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel Samnick filed Critical Samuel Samnick
Publication of NZ568367A publication Critical patent/NZ568367A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Soft Magnetic Materials (AREA)
NZ568367A 2005-11-25 2006-11-27 Treatment of malignant neoplasias using non-radioactive 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine NZ568367A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025776 2005-11-25
PCT/EP2006/011367 WO2007060011A1 (en) 2005-11-25 2006-11-27 Therapy of malignant neoplasias

Publications (1)

Publication Number Publication Date
NZ568367A true NZ568367A (en) 2010-11-26

Family

ID=37744207

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ568367A NZ568367A (en) 2005-11-25 2006-11-27 Treatment of malignant neoplasias using non-radioactive 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine

Country Status (15)

Country Link
US (1) US8268888B2 (https=)
EP (1) EP1962822B1 (https=)
JP (1) JP5108781B2 (https=)
KR (1) KR20080074193A (https=)
AT (1) ATE454144T1 (https=)
AU (1) AU2006316781B2 (https=)
CA (1) CA2630848C (https=)
DE (1) DE602006011650D1 (https=)
DK (1) DK1962822T3 (https=)
ES (1) ES2341575T3 (https=)
IL (1) IL191690A (https=)
NZ (1) NZ568367A (https=)
PL (1) PL1962822T3 (https=)
PT (1) PT1962822E (https=)
WO (1) WO2007060011A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948154C (en) 2014-05-07 2017-09-26 The University Of Akron Radioopaque, iodine functionalized phenylalanine-based poly(ester urea)s
WO2025202716A1 (en) * 2024-03-26 2025-10-02 Telix Pharmaceuticals (Innovations) Pty Ltd Combination therapy for treating glioblastomas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5816999A (en) * 1997-07-24 1998-10-06 Bischoff; Jeffrey Flexible catheter for the delivery of ionizing radiation to the interior of a living body
AU1932900A (en) * 1998-12-04 2000-06-26 Medivas, Llc Methods for detection of vulnerable plaques using a detectable lipid-avid agent
WO2004050168A2 (en) * 2002-11-27 2004-06-17 Board Of Regents, The University Of Texas System Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues

Also Published As

Publication number Publication date
KR20080074193A (ko) 2008-08-12
US8268888B2 (en) 2012-09-18
DK1962822T3 (da) 2010-05-17
EP1962822B1 (en) 2010-01-06
JP5108781B2 (ja) 2012-12-26
ES2341575T3 (es) 2010-06-22
DE602006011650D1 (de) 2010-02-25
PL1962822T3 (pl) 2010-07-30
AU2006316781A1 (en) 2007-05-31
WO2007060011A1 (en) 2007-05-31
AU2006316781B2 (en) 2012-06-14
JP2009517356A (ja) 2009-04-30
US20100003268A1 (en) 2010-01-07
ATE454144T1 (de) 2010-01-15
PT1962822E (pt) 2010-04-09
IL191690A0 (en) 2009-08-03
IL191690A (en) 2011-10-31
EP1962822A1 (en) 2008-09-03
CA2630848A1 (en) 2007-05-31
CA2630848C (en) 2014-10-07

Similar Documents

Publication Publication Date Title
JP7839135B2 (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用
Ma et al. In vitro and in vivo evaluation of 211At-labeled fibroblast activation protein inhibitor for glioma treatment
US10646599B2 (en) Method for upregulating antigen expression
O'Donnell et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6
Aft et al. Enhancing targeted radiotherapy by copper (II) diacetyl-bis (N 4-methylthiosemicarbazone) using 2-deoxy-D-glucose
HK1256497A1 (en) Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody
US20170348441A1 (en) Therapy of malignant neoplasias
KR20210095620A (ko) 암 치료 방법
AU2006316781B2 (en) Therapy of malignant neoplasias
US20110300067A1 (en) Methods for increasing efficacy of radioimmunotherapy of melanoma
Rathmann Development of a Versatile Platform for Combination Targeted Radionuclide and Immune Cell Recruitment Therapies Using Bio-Orthogonal Chemistry
WO2007060012A2 (en) Use of l-phenylalanine conjugated to an emitting isotope for therapy of hormone dependent carcinoma
JP2016210688A (ja) 放射性抗腫瘍剤、及び、抗腫瘍用キット
JP2024539952A (ja) 放射性核種錯体の組み合わせ療法
HK1217438B (en) Combination therapy comprising rituximab and the radiolabeled hh1 monoclonal antibody

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 NOV 2016 BY RENEWALS TEAM

Effective date: 20131123

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2017 BY RENEWALS TEAM

Effective date: 20161029

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2018 BY RENEWALS TEAM

Effective date: 20171109

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2019 BY RENEWALS TEAM

Effective date: 20181113

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2020 BY RENEWALS TEAM

Effective date: 20191119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2021 BY ENVOY

Effective date: 20201126

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2022 BY ENVOY

Effective date: 20211112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2023 BY ENVOY

Effective date: 20221122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2024 BY ENVOY

Effective date: 20231121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2025 BY ENVOY

Effective date: 20241120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2026 BY IPAN GMBH

Effective date: 20251106